||Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.
Shoji, Emi ,
Sakurai, Hidetoshi ,
Nishino, Tokiko ,
Nakahata, Tatsutoshi ,
Heike, Toshio ,
Awaya, Tomonari ,
Fujii, Nobuharu ,
Manabe, Yasuko ,
Matsuo, MasafumiSehara-Fujisawa, Atsuko
52015-08-20 , Nature Publishing Group
iPS細胞によりデュシェンヌ型筋ジストロフィーの初期病態を再現. 京都大学プレスリリース. 2015-08-21.
Duchenne muscular dystrophy (DMD) is a progressive and fatal muscle degenerating disease caused by a dystrophin deficiency. Effective suppression of the primary pathology observed in DMD is critical for treatment. Patient-derived human induced pluripotent stem cells (hiPSCs) are a promising tool for drug discovery. Here, we report an in vitro evaluation system for a DMD therapy using hiPSCs that recapitulate the primary pathology and can be used for DMD drug screening. Skeletal myotubes generated from hiPSCs are intact, which allows them to be used to model the initial pathology of DMD in vitro. Induced control and DMD myotubes were morphologically and physiologically comparable. However, electric stimulation of these myotubes for in vitro contraction caused pronounced calcium ion (Ca(2+)) influx only in DMD myocytes. Restoration of dystrophin by the exon-skipping technique suppressed this Ca(2+) overflow and reduced the secretion of creatine kinase (CK) in DMD myotubes. These results suggest that the early pathogenesis of DMD can be effectively modelled in skeletal myotubes induced from patient-derived iPSCs, thereby enabling the development and evaluation of novel drugs.